

RESEARCH ARTICLE

Open Access



Fecal carriage and molecular epidemiology of carbapenem-resistant Enterobacteriaceae from outpatient children in Shanghai

Fen Pan[†], Dongxing Tian[†], Bingjie Wang, Wantong Zhao, Huihong Qin, Tiandong Zhang and Hong Zhang^{* ID}

Abstract

Background: Fecal colonization with carbapenem-resistant Enterobacteriaceae (CRE) is a risk factor for bacterial translocation resulting in subsequent endogenous infections. The purpose of this study is to investigate the prevalence of CRE strains colonization in stool samples of outpatient in a tertiary pediatric hospital of Shanghai, China.

Methods: In a retrospective study, fecal samples were consecutively obtained from patients in 2016 and screening test for CRE was conducted by using home-made MacConkey agar. Antimicrobial susceptibility was determined by the broth microdilution method and β -lactamases were characterized by polymerase chain reaction (PCR) assays and DNA sequencing. Multilocus sequence typing (MLST) was performed for the genetic relationships of the isolates.

Results: A total of 880 fecal samples were included for this screening test and 32 CRE strains were identified in 32 non-duplicate fecal samples from 32 children (1.3 ± 1.5 years), with a carriage rate of 3.6%. These strains mainly distributed in *Klebsiella pneumoniae* (37.5%) and *Escherichia coli* (37.5%). All CRE strains showed high resistance to most of the routinely used antibiotics (> 90%) except for polymyxin B and tigecycline. The *bla*_{NDM} gene was the major carbapenemase gene harbored by gastrointestinal CRE strains, followed by *bla*_{KPC-2}, *bla*_{IMP-26}, and *bla*_{IMP-4}. Other β -Lactamase genes including *bla*_{CTX-M}, *bla*_{SHV}, *bla*_{TEM-1}, and *bla*_{DHA-1} were also detected. MLST analysis revealed that various sequence types (STs) were detected in these strains, with ST11 and ST37 being more prevalent in *K.pneumoniae* and ST101 in *E.coli*.

Conclusions: This study revealed the prevalence of CRE fecal carriage in children from outpatient and urgent implementation of infection control measure should be conducted to limit the spread of CRE strains.

Keywords: Carbapenem-resistant Enterobacteriaceae, Fecal carriage, Molecular epidemiology, Carbapenemase, Outpatient children

Background

Carbapenems such as imipenem and meropenem are often recommended as antimicrobial agents of the last resort, especially in cases where extended-spectrum β -Lactamase (ESBL) producing organisms involved [1]. Since the KPC1 carbapenem-resistant *Klebsiella pneumoniae* was first isolated in the United States of America [2], the prevalence of carbapenem-resistant Enterobacteriaceae (CRE) has emerged as a public health problem and given rise to epidemic outbreaks in hospital surroundings

all around the world [3–5]. According to the CHINET surveillance of bacterial resistance data in China, CRE strains showed high levels of resistance to most antibiotics and the rates of carbapenem resistance in *E. coli* and *K. pneumoniae* had increased from 0 and 2.9% in 2005 to 1 and 13.4% in 2014, respectively [6]. In general, the mechanism of resistance to carbapenems is mainly associated with the production of carbapenemases.

Enterobacteriaceae are a family of bacteria that mainly colonize in normal human intestines. Gastrointestinal tract colonization with CRE strains can be a risk factor for bacterial translocation resulting in subsequent endogenous infections in immunocompromised children [7]. As Das et al. reported that neonates with Gram

* Correspondence: schjyk2015@126.com

[†]Fen Pan and Dongxing Tian contributed equally to this work.

Department of clinical laboratory, Shanghai Children's Hospital, Shanghai Jiaotong University, Luding Road 355, Putuo District, Shanghai 200062, China



negative bacilli in the gut had a higher incidence of clinical sepsis than those without these bacteria [8]. The acquisition of mobile genetic elements may be involved in the horizontal transmission. Several studies have been conducted to investigate the fecal carriage characteristics of CRE strains among inpatients [9–11], however, there are few data regarding the prevalence of CRE colonization in community settings, especially in China. Therefore, this research retrospectively aimed to conduct a surveillance of molecular epidemiology of CRE strains colonized in stool samples of outpatient children in a tertiary pediatric hospital of Shanghai, China.

Methods

Specimen collection and bacterial screening

This study was retrospectively conducted in 2016 from January to December at Shanghai Children's Hospital, which is one of largest pediatric hospitals with 700 beds. Epidemiological information including patient demographics, prior hospitalization, previous receipt of antibiotic therapy, and invasive operation during hospitalization was obtained from the medical records of each patient.

Fecal samples were consecutively obtained from patients of ≤ 18 year old attending in outpatient clinics, who received the fecal culture testing. Approximately 0.5 mg of stool or a rectal swab from each patient was stored in Cary-Blair transport medium (Hopebio, Qingdao, China) in 4 °C condition up to 1 days prior to testing. Screening test of CRE was performed as follows: fecal samples were inoculated in home-made MacConkey agar supplemented with meropenem at 1 $\mu\text{g}/\text{ml}$ and then incubated at 35 °C in a 5% CO₂ incubator. After incubation for 24–48 h, the growth of at least one colony per agar plate was considered as positive screening result and the strain was further investigated. All CRE strains were stored at –80 °C in 40% glycerol broth medium for further analysis.

Identification and antimicrobial susceptibility testing

All CRE bacteria were identified by matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry using MALDI Biotyper (Bruker Daltonik GmbH, Bremen, Germany). Antimicrobial susceptibility testing of all CRE strains against amikacin, cefotaxime, ceftazidime, cefepime, piperacillin-tazobactam, ertapenem, imipenem, meropenem, ciprofloxacin, fosfomycin, aztreonam, colistin, and tigecycline was carried out by using broth microdilution method for determining the minimal inhibitory concentrations (MICs). The breakpoints used for interpretation were recommended by the Clinical and Laboratory Standards Institute (CLSI) 2017 [12]. Quality control was managed by using *E. coli* ATCC 25922. The EUCAST breakpoints were used for colistin. The interpretive criterion for tigecycline was based on the breakpoints of the Food and Drug Administration (FDA).

Screening for carbapenemase and other resistance genes

Polymerase chain reaction (PCR) was used to detect carbapenemase genes (*bla*_{NDM}, *bla*_{KPC}, *bla*_{IMP}, *bla*_{VIM}, *bla*_{OXA-48}, *bla*_{GES}, *bla*_{GIM}, and *bla*_{SIM}), ESBL genes (*bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV}), AmpC genes (*bla*_{DHA}, *bla*_{CMY}, *bla*_{MOX}, *bla*_{EBC}, and *bla*_{AAC}), and the colistin resistance gene (*mcr-1*) as previously described [13–15]. Amplicons were sequenced and nucleotide sequences were further analyzed and compared to sequences available at the National Center for Biotechnology Information (NCBI) website (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Multilocus sequence typing (MLST)

MLST was performed for the genetic relationship according to the previous protocol described. Seven housekeeping genes including *ropB*, *gapA*, *mdh*, *pgi*, *phoE*, *infB*, and *tonB* were amplified and sequenced for *K. pneumoniae* [16]. Alleles and sequence types (STs) were assigned at the Pasteur Institute MLST website (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html>). For *E. coli*, the housekeeping genes of *adk*, *fumC*, *gyrB*, *icd*, *mdh*, *purA*, and *recA* were amplified and sequenced [17], and STs were then further assigned by using the MLST database (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>). The seven housekeeping genes of *Enterobacter cloacae* (*dnaA*, *fusA*, *gyrB*, *leuS*, *pyrG*, *rplB*, and *rpoB*) were also amplified and sequenced [18], and STs were assigned at the MLST website (<https://pubmlst.org/ecloacae/>).

Statistical analysis

Statistical analysis was performed by using SPSS 19.0 for Windows (version 19.0; SPSS Inc., Chicago, IL, USA). The quantitative data were expressed as means \pm standard deviations (SD). Categorical variables, expressed as numbers and percentages, were compared by the Chi-square or Fisher's exact test. A value of $P \leq 0.05$ was considered statistically significant. Antimicrobial resistance data was analyzed by using WHONET 5.6.

Results

Screening result and patient information

During the study period, a total of 880 fecal samples from 880 children (1.1 ± 2.2 years) in outpatient clinics were collected for this screening test. 32 non-duplicate samples were detected as being CRE positive with a carriage rate of 3.6% (32/880). The 32 Enterobacteriaceae strains included *K. pneumoniae* ($n = 12$, 37.5%), *E. coli* ($n = 12$, 37.5%), *E. cloacae* ($n = 6$, 18.8%), *Enterobacter aerogenes* ($n = 1$, 3.1%), and *Raoultella planticola* ($n = 1$, 3.1%).

The CRE strains were isolated from 32 individual children (19 male and 13 female) whose mean age was 1.3 ± 1.5 years (rang: 1 m–5y). Among these children, 28.1% (9/32) had a history of prior hospitalization in

recent 3 months and these patients also had received therapy with antibiotics (e.g. imipenem, ceftazidime-sulbactam, ampicillin/sulbactam, or cefotaxime). Of the 32 CRE carriers and 848 non-CRE carriers identified, 9 (28.1%) and 38 (4.5%) children, respectively, had been hospitalized and received antibiotics within the past 3 months ($P < 0.05$). Among nine previously hospitalized CRE carrier children, only two children had received invasive operation during their hospitalization.

Antimicrobial susceptibility

The results of the antimicrobial susceptibility testing of the 32 CRE strains are shown in Table 1. All CRE isolates showed high resistance to cephalosporins and carbapenems (> 95%). The rates of susceptibility to amikacin, ciprofloxacin, aztreonam and fosfomycin were 75, 25, 21.6, and 15.6%, respectively. Tigecycline retained excellent activity against all 32 CRE isolates, with a susceptibility rate of 100%, regardless of the species. Additionally, the CRE strains showed a high susceptibility rate to colistin (90.6%). However, the MIC ≥ 4 $\mu\text{g/mL}$ of colistin was observed in *E.coli* and *E.cloacae* isolates.

Carbapenemase and other resistance genes

Among the isolated CRE strains, the NDM-1 type carbapenemase gene (bla_{NDM-1}) was the most common and detected in 14 strains (43.8%, 14/32), followed by bla_{NDM-5} gene (18.8%, 6/32). Other carbapenemase genes including bla_{KPC-2} , bla_{IMP-26} , and bla_{IMP-4} were also found. The characteristics of the *E.coli* and *K.pneumoniae* isolates are shown in Tables 2 and 3, respectively. For *E.coli* strains, only the bla_{NDM-1} and bla_{NDM-5} genes were detected, whereas bla_{NDM-1} , bla_{NDM-5} , bla_{KPC-2} , and bla_{IMP-4} were

found in the *K.pneumoniae* strains. The bla_{IMP-26} carbapenemase gene was only observed in *E.cloacae*.

A majority of CRE strains simultaneously harbored ESBL genes. The dominant ESBL gene was bla_{CTX-M} . The common subtypes of bla_{CTX-M} in these strains were $bla_{CTX-M-14}$ ($n = 19$), $bla_{CTX-M-15}$ ($n = 9$), and $bla_{CTX-M-65}$ ($n = 1$). Other ESBL genes including bla_{SHV-1} , bla_{SHV-2} , bla_{SHV-11} , bla_{TEM-1} , and $bla_{TEM-214}$ were also detected. The bla_{DHA-1} gene, which is an AmpC gene, was found in five isolates. No *mcr-1* gene was identified in all strains.

Characteristics of STs

MLST analysis revealed that STs distributed dispersedly in different species colonized in fecal samples from community and a total of twenty distinct STs were identified among 32 CRE isolates, with various STs in different species. As depicted in Table 3, nine STs were observed among carbapenem-resistant *E.coli* and ST101 was main type, accounting for 33.3%. We also found seven STs in carbapenem-resistant *K.pneumoniae* isolates, with ST11 being the major type (Table 2). Then four STs were identified in the six *E.cloacae* isolates.

Discussion

Investigation of the fecal carriage prevalence of CRE among outpatients from the community setting can help us to better understand the origin of CRE isolates responsible for outbreak events and contribute to control CRE dissemination. Our study displayed that the rate of colonization with CRE in fecal sample collected from children in outpatient visits was 3.6%, which was lower than what had been reported in patients from community setting in other countries [10, 19]. Several reasons contribute to this phenomenon of the colonization of CRE isolates in rectal gastrointestinal tract. Firstly, further analysis of patient information of CRE carriers showed that 28.1% of them had a history of prior hospitalization in recent 3 months and also had received therapy with antibiotics, but only 4.5% of non-carriers had. Previous studies reported that exposure to hospital setting or/and antimicrobial agents might increase the risk of colonization and it would be easier to acquire CRE isolates, which may also explain the occurrence in community-onset cases [20, 21]. However, despite the previous studies showed an increased risk of CRE carriage with hospital exposure, there is no significance between the min, max and mean times of hospitalization for the CRE and non-CRE groups with recent hospital exposure in this study. What is more, many outpatients receive antimicrobial treatment without the advice or prescription of a physician or other trained health care provider. Last but not least, CRE strains could spread via physical contact with other people and have the propensity to acquire genetic materials mostly in the form of plasmids and transposons through horizontal gene

Table 1 Antimicrobial susceptibility profiles of carbapenem-resistant Enterobacteriaceae strains from fecal samples, % (n)

Antibiotics	Resistant	Intermediate	Susceptible
Cefotaxime	100 (32)	0 (0)	0 (0)
Ceftazidime	100 (32)	0 (0)	0 (0)
Cefepime	100 (32)	0 (0)	0 (0)
Piperacillin-tazobactam	78.1 (25)	6.3 (2)	15.6 (5)
Ertapenem	96.9 (31)	3.1 (1)	0 (0)
Imipenem	96.9 (31)	3.1 (1)	0 (0)
Meropenem	96.9 (31)	3.1 (1)	0 (0)
Amikacin	25 (8)	0 (0)	75 (24)
Ciprofloxacin	71.9 (23)	3.1 (1)	25 (8)
Fosfomycin	81.2 (26)	3.1 (1)	15.6 (5)
Aztreonam	78.1 (25)	0 (0)	21.9 (7)
Colistin	9.4 (3)	0 (0)	90.6 (29)
Tigecycline	0 (0)	0 (0)	100 (32)

Table 2 Characteristics of carbapenem-resistant *Klebsiella pneumoniae* colonized in fecal samples

NO.	Carbapenemase	Other resistance genes	MLST	MIC ($\mu\text{g/mL}$)												
				AK	FEP	CTX	CAZ	TZP	ETP	MEM	IPM	CIP	ATM	FOS	COL	TGC
16439	NDM-1	CTX-M-14, SHV-2, DHA-1	ST14	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	32	128	32	16	128	≥ 512	1	≤ 0.125
60006	NDM-1	CTX-M-14	ST11	≥ 256	128	≥ 256	≥ 256	$\geq 256/4$	64	128	64	32	≤ 4	≥ 256	1	≤ 0.125
E17	NDM-1	CTX-M-14	ST11	≥ 256	128	≥ 256	≥ 256	256/4	256	256	64	128	≥ 256	256	1	≤ 0.125
52084	NDM-1	CTX-M-14, SHV-2, TEM-214	ST37	≥ 256	128	≥ 256	≥ 256	256/4	256	256	64	128	≥ 256	256	1	≤ 0.125
53706	IMP-4	CTX-M-14, TEM-1, SHV-11	ST17	≤ 16	64	128	≥ 256	32/4	4	16	4	≤ 1	≤ 4	≥ 256	1	0.25
E1	NDM-5	CTX-M-15, SHV-11	ST48	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	≥ 256	≥ 256	256	≤ 1	≥ 256	≥ 256	1	≤ 0.125
E3	NDM-5	CTX-M-15, SHV-11	ST792	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	128	256	128	4	32	256	1	0.25
E6	NDM-5	CTX-M-15, SHV-11	ST48	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	≥ 256	≥ 256	≥ 256	8	128	≥ 256	1	≤ 0.125
E8	KPC-2	–	ST11	≥ 256	≥ 256	≥ 256	≥ 256	$\geq 256/4$	128	256	128	64	≥ 256	≥ 256	1	0.25
E9	NDM-1	CTX-M-15, SHV-1	ST37	≤ 16	64	≥ 256	≥ 256	$\geq 256/4$	32	128	16	≤ 1	128	≤ 64	1	≤ 0.125
E11	KPC-2	–	ST11	≥ 256	64	128	≥ 256	$\geq 256/4$	128	256	32	64	≥ 256	≥ 256	1	≤ 0.125
E27	KPC-2	CTX-M-65, SHV-1	ST215	≤ 16	32	128	256	$\leq 16/4$	1	4	4	≤ 1	≤ 4	256	1	0.25

AK amikacin, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, TZP piperacillin-tazobactam, ETP ertapenem, IPM imipenem, MEM meropenem, CIP ciprofloxacin, FOS fosfomycin, ATM aztreonam, COL colistin, TGC tigecycline

transfer [22]. Colonization with CRE strain plays an important role in transmission of the organism through horizontal gene transfer in health care settings [22].

The surveillance definition for CRE are designed that Enterobacteriaceae are resistant to imipenem, meropenem, doripenem, or ertapenem or is document that the isolate possess a carbapenemase and CRE are reported to be commonly identified in *K.pneumoniae*, *E.coli*, and *E.cloacae* [23, 24]. The major resistance mechanism of CRE is the production of carbapenemases such as NDM, KPC, and IMP, which were also observed in this study. The NDM type, including NDM-1 and NDM-5, is found

to be the key carbapenemase responsible for mediating development of the carbapenem resistance phenotypes in children [3, 25]. NDM-1 and its minor variants, a class B carbapenemase first clinically isolated from a patient at a hospital in New Delhi, India, has since been identified all over the world and only detected in *E.coli* and *K.pneumoniae* [26–29]. Consistent with the above findings, most of the *E.coli* and *K.pneumoniae* colonized CREs in the fecal samples in the present study harbored the *bla*_{NDM} gene and a previous study in our hospital also has reported the outbreak of CRE strains caused by NDM-1 producing *K.pneumoniae* among neonates [3].

Table 3 Characteristics of carbapenem-resistant *Escherichia coli* colonized in fecal samples

NO.	Carbapenemase	Other resistance genes	MLST	MIC ($\mu\text{g/mL}$)												
				AK	FEP	CTX	CAZ	TZP	ETP	MEM	IPM	CIP	ATM	FOS	COL	TGC
16366	–	CTX-M-14	ST7151	≤ 16	≥ 256	≥ 256	128	$\leq 16/4$	16	8	16	16	128	≥ 512	1	≤ 0.125
16495	NDM-1	CTX-M-14	ST101	≤ 16	≥ 256	≥ 256	64	$\leq 16/4$	16	8	16	16	128	≥ 512	1	≤ 0.125
24354	NDM-5	CTX-M-14	ST167	≤ 16	32	≥ 256	64	$\leq 16/4$	32	16	32	16	128	≥ 256	1	≤ 0.125
27291	–	CTX-M-14, DHA-1	ST2003	≤ 16	≥ 256	≥ 256	256	256/4	32	8	16	16	128	≥ 256	1	≤ 0.125
60286	NDM-1	CTX-M-14	ST10	≤ 16	64	≥ 256	≥ 256	$\geq 256/4$	32	128	32	32	64	≥ 256	1	≤ 0.125
60066	NDM-5	CTX-M-15	ST457	≥ 256	128	≥ 256	≥ 256	$\geq 256/4$	64	128	64	32	≤ 4	≥ 256	1	≤ 0.125
60883	NDM-1	CTX-M-14, DHA-1	ST101	≤ 16	64	≥ 256	≥ 256	$\geq 256/4$	256	128	32	16	≥ 256	≥ 256	1	≤ 0.125
44376	NDM-1	CTX-M-14	ST648	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	256	256	64	64	≤ 4	≤ 64	1	≤ 0.125
48556	NDM-1	CTX-M-14, DHA-1	ST101	≤ 16	128	≥ 256	≥ 256	$\geq 256/4$	8	16	8	8	128	≤ 64	4	0.25
50831	NDM-1	CTX-M-14	ST101	≥ 256	≥ 256	≥ 256	≥ 256	$\geq 256/4$	64	64	32	128	≥ 256	≥ 256	≥ 4	≤ 0.125
55414	–	CTX-M-14	ST12	≤ 16	≥ 256	≥ 256	≥ 256	$\geq 256/4$	16	64	32	64	32	≤ 64	1	≤ 0.125
E10	NDM-5	CTX-M-15, TEM-1	ST68	≤ 16	64	≥ 256	≥ 256	$\geq 256/4$	128	128	64	2	≤ 4	≤ 64	1	≤ 0.125

AK amikacin, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, TZP piperacillin-tazobactam, ETP ertapenem, IPM imipenem, MEM meropenem, CIP ciprofloxacin, FOS fosfomycin, ATM aztreonam, COL colistin, TGC tigecycline

NDM-1 producing *K.pneumoniae* are highly resistant pathogens with no effective beta-lactams, including recent ones such as ceftolozane tazobactam and ceftazidime avibactam and the only one that works is aztreonam [30]. Additionally, only three *K.pneumoniae* strains carried *bla*_{KPC-2} gene, which was mostly prevalent in adults population [31], were found in this study. IMP type carbapenemases (IMP-4 and IMP-26) were observed in *E.cloacae* and *K.pneumoniae*, but not in *E.coli*. However, it is remarkable that no carbapenemase resistance genes were detected in 9.4% (3/32) of the CRE strains. This finding suggests that a new mechanism might contribute to the resistance to carbapenems and further studies into this mechanism should be conducted.

Molecular analysis revealed a high level of genetic diversity, including ST101, ST11, ST37, and ST48, and several STs are clearly related to specific bacteria, and are prevalent all over the world. The most common STs of CRE in *K.pneumoniae* were ST11 and ST37. Interestingly, the carbapenem-resistant *K.pneumoniae* harboring *bla*_{KPC-2} belonged to ST11, which exhibited signs of multi-clonal dissemination and caused a series of outbreaks in China [32, 33]. Additionally, another carbapenem-resistant *K.pneumoniae* harboring *bla*_{NDM-1} belonged to ST37 and this ST had been identified previously during an outbreak of this phenotype in our hospital [3]. Clonally diverse carbapenem-resistant *E.coli* (ST405, ST131, ST156 and ST101) have been reported globally, and ST101 was the predominant ST isolated in this study. The ST101 type of *E.coli* produced NDM-1 carbapenemase, a phenotype that has been linked to nosocomial transmission in Korea [34].

Importantly, children with CRE strains in fecal samples are considered as a high risk group by World Health Organization (WHO), which can spread CRE by intimate contact and travel [35]. The origin of CRE isolates in these children remains unknown and it is the main limitation that we don't know if the source of the described CRE carriage in these children is the result of transmission in the community or in the hospital. Screening for CRE at discharge may provide an explanation for this hypothesis. Exposure to antimicrobial agents in both the hospital setting and environments is always the key to acquisition. Also we know that children are at high risk for multi-drug organism carriage and further studies should be carried out to evaluate the phenomenon of the original source of CRE strains.

Conclusions

In summary, the current data reveal the prevalence of CRE colonization in fecal sample from pediatric outpatients and strategies to control the dissemination of antimicrobial resistant isolates from stool to other sterilized sites should be developed. Children who had hospitalization exposure

should be screened for CRE at discharge, which may help to definitively establish where acquisition of CRE is truly occurring and decrease the occurrence and transmission of CRE in children group.

Abbreviations

CLSI: Clinical laboratory standard institute; CRE: Carbapenem-resistant Enterobacteriaceae; ESBL: Extended-spectrum β -Lactamase; MALDI-TOF: Matrix-assisted laser desorption ionization time of flight; MLST: Multilocus sequence typing; PCR: Polymerase chain reaction; ST: Sequence type

Acknowledgements

The authors thank all the patients who contributed their specimens to this study. We also thank the microbiologists and technical staff from Shang Children's hospital.

Authors' contributions

Conceived and designed the experiments: HZ; Performed the experiments: FP, DT, BW, HQ, TZ; Analyzed the data: FP, WZ; Wrote the manuscript: FP; All authors read and approved the final manuscript.

Funding

This work was supported by fundings from Fen Pan receiving from youth foundation of Shanghai Municipal Commission of Health and Family Planning (20154Y0159) and Dr. Hong Zhang receiving from Shanghai Municipal Commission of Health and Family Planning (2015ZB0203). The funders had no role in the design of the study, collection, analysis and interpretation of the data, or in writing the manuscript.

Availability of data and materials

Please contact corresponding author for data requests.

Ethics approval and consent to participate

This study was approved by the ethics committee of Shanghai Children's Hospital. Written informed consent was obtained from the patients' guardians on behalf of the children enrolled in this study.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Received: 22 August 2018 Accepted: 18 July 2019

Published online: 01 August 2019

References

- Chiotos K, Han JH, Tamma PD. Carbapenem-resistant Enterobacteriaceae infections in children [J]. *Curr Infect Dis Rep*. 2016;18:2.
- Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae* [J]. *Antimicrob Agents Chemother*. 2001;45:1151–61.
- Zhu J, Sun L, Ding B, Yang Y, Xu X, Liu W, et al. Outbreak of NDM-1-producing *Klebsiella pneumoniae* ST76 and ST37 isolates in neonates [J]. *Eur J Clin Microbiol Infect Dis*. 2016;35:611–8.
- Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB, et al. Multicenter study of the risk factors for colonization or infection with Carbapenem-resistant Enterobacteriaceae in children [J]. *Antimicrob Agents Chemother*. 2017;61. <https://doi.org/10.1128/AAC.01440-17>
- Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to Carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States [J]. *Antimicrob Agents Chemother*. 2017;61. <https://doi.org/10.1128/AAC.02349-16>
- Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014 [J]. *Clin Microbiol Infect*. 2016;22(Suppl 1):S9–14.

7. Mittal G, Gaidn R, Kumar D, Kaushik G, Gupta KB, Verma PK, et al. Risk factors for fecal carriage of carbapenemase producing Enterobacteriaceae among intensive care unit patients from a tertiary care center in India [J]. *BMC Microbiol.* 2016;16:138.
8. Das P, Singh AK, Pal T, Dasgupta S, Ramamurthy T, Basu S. Colonization of the gut with gram-negative bacilli, its association with neonatal sepsis and its clinical relevance in a developing country [J]. *J Med Microbiol.* 2011;60:1651–60.
9. Vaishnavi C. Translocation of gut flora and its role in sepsis [J]. *Indian J Med Microbiol.* 2013;31:334–42.
10. Abdallah HM, Alnaiemi N, Reuland EA, Wintermans BB, Koek A, Abdelwahab AM, et al. Fecal carriage of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital-based cross-sectional study [J]. *Antimicrob Resist Infect Control.* 2017;6:62.
11. Joo EJ, Kim SJ, Baek M, Choi Y, Seo J, Yeom JS, et al. Fecal carriage of antimicrobial-resistant Enterobacteriaceae in healthy Korean adults [J]. *J Microbiol Biotechnol.* 2018;28:1178–84.
12. CLSI. Performance standards for antimicrobial susceptibility testing. 27th ed CLSI supplement M100 [J]. Wayne: Clinical and Laboratory Standards Institute; 2017.
13. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae [J]. *J Antimicrob Chemother.* 2010;65:490–5.
14. Du J, Li P, Liu H, Lu D, Liang H, Dou Y. Phenotypic and molecular characterization of multidrug resistant *Klebsiella pneumoniae* isolated from a university teaching hospital, China [J]. *PLoS One.* 2014;9:e95181.
15. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study [J]. *Lancet Infect Dis.* 2016;16:161–8.
16. Diancourt L, Passet V, Verhoef J, Grimont PA, Bricse S. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates [J]. *J Clin Microbiol.* 2005;43:4178–82.
17. Tartof SY, Solberg OD, Manges AR, Riley LW. Analysis of a uropathogenic *Escherichia coli* clonal group by multilocus sequence typing [J]. *J Clin Microbiol.* 2005;43:5860–4.
18. Miyoshi-Akiyama T, Hayakawa K, Ohmagari N, Shimojima M, Kirikae T. Multilocus sequence typing (MLST) for characterization of *Enterobacter cloacae* [J]. *PLoS One.* 2013;8:e66358.
19. Rai S, Das D, Niranjana DK, Singh NP, Kaur IR. Carriage prevalence of carbapenem-resistant Enterobacteriaceae in stool samples: a surveillance study [J]. *Australas Med J.* 2014;7:64–7.
20. Salomao MC, Guimaraes T, Duailibi DF, Perondi MBM, Letaif LSH, Montal AC, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate [J]. *J Hosp Infect.* 2017;97:241–6.
21. Mohan B, Prasad A, Kaur H, Hallur V, Gautam N, Taneja N. Fecal carriage of carbapenem-resistant Enterobacteriaceae and risk factor analysis in hospitalised patients: a single Centre study from India [J]. *Indian J Med Microbiol.* 2017;35:555–62.
22. Shu LB, Lu Q, Sun RH, Lin LQ, Sun QL, Hu J, et al. Prevalence and phenotypic characterization of carbapenem-resistant *Klebsiella pneumoniae* strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, China [J]. *Infect Drug Resist.* 2019;12:11–8.
23. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of Carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network [J]. *Antimicrob Agents Chemother.* 2018;62. <https://doi.org/10.1128/AAC.01882-17>
24. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, et al. Nationwide surveillance of clinical Carbapenem-resistant Enterobacteriaceae (CRE) strains in China [J]. *EBioMedicine.* 2017;19:98–106.
25. Tian D, Pan F, Wang C, Sun Y, Zhang H. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* among pediatric patients in Shanghai [J]. *Infect Drug Resist.* 2018;11:1935–43.
26. Moellering RC Jr. NDM-1—a cause for worldwide concern [J]. *N Engl J Med.* 2010;363:2377–9.
27. Liu Z, Li W, Wang J, Pan J, Sun S, Yu Y, et al. Identification and characterization of the first *Escherichia coli* strain carrying NDM-1 gene in China [J]. *PLoS One.* 2013;8:e66666.
28. Pollett S, Miller S, Hindler J, Uslan D, Carvalho M, Humphries RM. Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013 [J]. *J Clin Microbiol.* 2014;52:4003–9.
29. Giske CG, Froding I, Hasan CM, Turlej-Rogacka A, Toleman M, Livermore D, et al. Diverse sequence types of *Klebsiella pneumoniae* contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom [J]. *Antimicrob Agents Chemother.* 2012;56:2735–8.
30. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime-avibactam and Aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by Metallo-beta-lactamases in Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2017;61. <https://doi.org/10.1128/AAC.01008-17>
31. Zheng B, Dai Y, Liu Y, Shi W, Dai E, Han Y, et al. Molecular epidemiology and risk factors of Carbapenem-resistant *Klebsiella pneumoniae* infections in eastern China [J]. *Front Microbiol.* 2017;8:1061.
32. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* in a Chinese hospital: a molecular epidemiological study [J]. *Lancet Infect Dis.* 2018;18:37–46.
33. Liu J, Yu J, Chen F, Yu J, Simner P, Tamma P, et al. Emergence and establishment of KPC-2-producing ST11 *Klebsiella pneumoniae* in a general hospital in Shanghai, China [J]. *Eur J Clin Microbiol Infect Dis.* 2018;37:293–9.
34. Yoo JS, Kim HM, Koo HS, Yang JW, Yoo JI, Kim HS, et al. Nosocomial transmission of NDM-1-producing *Escherichia coli* ST101 in a Korean hospital [J]. *J Antimicrob Chemother.* 2013;68:2170–2.
35. Schwartz KL, Morris SK. Travel and the spread of drug-resistant Bacteria [J]. *Curr Infect Dis Rep.* 2018;20:29.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

